HDS screening with patient-derived primary cells guided individualized therapy for esophageal squamous cell carcinoma–in vivo and vitro
ObjectiveTo analyze and evaluate the role of the High-throughput Drug Sensitivity (HDS) screening strategy in identifying highly sensitive drugs against esophageal squamous cell carcinoma (ESCC).MethodsA total of 80 patients with progressive ESCC were randomly divided into the observation (40 cases)...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1212851/full |
| _version_ | 1797756644234362880 |
|---|---|
| author | Xing He Hezhong Yan Jie Hu Xiaowei Duan Mingjin Zhang Haiqing Li Jiaoxue Wang Qian Gao Senyuan Yu Xilu Hou Guobin Liao Shicun Guo Jin Li Yurong Ge Xiaolan Chen Wenchao Wang Jun Tang |
| author_facet | Xing He Hezhong Yan Jie Hu Xiaowei Duan Mingjin Zhang Haiqing Li Jiaoxue Wang Qian Gao Senyuan Yu Xilu Hou Guobin Liao Shicun Guo Jin Li Yurong Ge Xiaolan Chen Wenchao Wang Jun Tang |
| author_sort | Xing He |
| collection | DOAJ |
| description | ObjectiveTo analyze and evaluate the role of the High-throughput Drug Sensitivity (HDS) screening strategy in identifying highly sensitive drugs against esophageal squamous cell carcinoma (ESCC).MethodsA total of 80 patients with progressive ESCC were randomly divided into the observation (40 cases) and the control groups (40 cases). In the observation group, primary ESCC cells were isolated from the tumor tissues with a gastroscope, and drug sensitivity screening was performed on cells derived from the 40 ESCC cases using the HDS method, followed by verification in a patient-derived tumor xenograft (PDX) mouse model. Finally, the differences in the therapeutic efficacy (levels of CEA, CYFRA21-1, SCCA after chemotherapy and the rates of overall survival, local progression, and distant metastasis at 12 months and 18 months time points after chemotherapy) were compared between the observation group (Screened drug-treated) and the control group (Paclitaxel combined with cisplatin regimen-treated).ResultsForty ESCC patients were screened for nine different high-sensitive chemotherapeutics, with the majority showing sensitivity to Bortezomib. Experiments on animal models revealed that the tumor tissue mass of PDX mice treated with the HDS-screened drug was significantly lower than that of the Paclitaxel-treated mice (p < 0.05), and the therapeutic efficacy of the observation group was better than the control group (p < 0.05).ConclusionHDS screening technology can be beneficial in screening high-efficacy anticancer drugs for advanced-stage ESCC patients, thereby minimizing adverse drug toxicity in critically ill patients. Moreover, this study provides a new avenue for treating advanced ESCC patients with improved outcomes. |
| first_indexed | 2024-03-12T18:04:32Z |
| format | Article |
| id | doaj.art-838fe524021c42f2896dc9818eb10ce1 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-03-12T18:04:32Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-838fe524021c42f2896dc9818eb10ce12023-08-02T09:31:02ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2023-08-011010.3389/fmed.2023.12128511212851HDS screening with patient-derived primary cells guided individualized therapy for esophageal squamous cell carcinoma–in vivo and vitroXing He0Hezhong Yan1Jie Hu2Xiaowei Duan3Mingjin Zhang4Haiqing Li5Jiaoxue Wang6Qian Gao7Senyuan Yu8Xilu Hou9Guobin Liao10Shicun Guo11Jin Li12Yurong Ge13Xiaolan Chen14Wenchao Wang15Jun Tang16Department of Gastroenterology, The 901th Hospital of Joint Logistics Support Force, Hefei, Anhui, ChinaDepartment of Gastroenterology, The 901th Hospital of Joint Logistics Support Force, Hefei, Anhui, ChinaAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, ChinaDepartment of Gastroenterology, The 901th Hospital of Joint Logistics Support Force, Hefei, Anhui, ChinaDepartment of Gastroenterology, The 901th Hospital of Joint Logistics Support Force, Hefei, Anhui, ChinaDepartment of Gastroenterology, The 901th Hospital of Joint Logistics Support Force, Hefei, Anhui, ChinaDepartment of Gastroenterology, The 901th Hospital of Joint Logistics Support Force, Hefei, Anhui, ChinaDepartment of Gastroenterology, The 901th Hospital of Joint Logistics Support Force, Hefei, Anhui, ChinaDepartment of Gastroenterology, The 901th Hospital of Joint Logistics Support Force, Hefei, Anhui, ChinaDepartment of Gastroenterology, The 901th Hospital of Joint Logistics Support Force, Hefei, Anhui, ChinaDepartment of Gastroenterology, The 901th Hospital of Joint Logistics Support Force, Hefei, Anhui, ChinaDepartment of Gastroenterology, The 901th Hospital of Joint Logistics Support Force, Hefei, Anhui, ChinaDepartment of Gastroenterology, The 901th Hospital of Joint Logistics Support Force, Hefei, Anhui, ChinaDepartment of Gastroenterology, The 901th Hospital of Joint Logistics Support Force, Hefei, Anhui, ChinaDepartment of Gastroenterology, The 901th Hospital of Joint Logistics Support Force, Hefei, Anhui, ChinaAnhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, ChinaDepartment of Gastroenterology, The 901th Hospital of Joint Logistics Support Force, Hefei, Anhui, ChinaObjectiveTo analyze and evaluate the role of the High-throughput Drug Sensitivity (HDS) screening strategy in identifying highly sensitive drugs against esophageal squamous cell carcinoma (ESCC).MethodsA total of 80 patients with progressive ESCC were randomly divided into the observation (40 cases) and the control groups (40 cases). In the observation group, primary ESCC cells were isolated from the tumor tissues with a gastroscope, and drug sensitivity screening was performed on cells derived from the 40 ESCC cases using the HDS method, followed by verification in a patient-derived tumor xenograft (PDX) mouse model. Finally, the differences in the therapeutic efficacy (levels of CEA, CYFRA21-1, SCCA after chemotherapy and the rates of overall survival, local progression, and distant metastasis at 12 months and 18 months time points after chemotherapy) were compared between the observation group (Screened drug-treated) and the control group (Paclitaxel combined with cisplatin regimen-treated).ResultsForty ESCC patients were screened for nine different high-sensitive chemotherapeutics, with the majority showing sensitivity to Bortezomib. Experiments on animal models revealed that the tumor tissue mass of PDX mice treated with the HDS-screened drug was significantly lower than that of the Paclitaxel-treated mice (p < 0.05), and the therapeutic efficacy of the observation group was better than the control group (p < 0.05).ConclusionHDS screening technology can be beneficial in screening high-efficacy anticancer drugs for advanced-stage ESCC patients, thereby minimizing adverse drug toxicity in critically ill patients. Moreover, this study provides a new avenue for treating advanced ESCC patients with improved outcomes.https://www.frontiersin.org/articles/10.3389/fmed.2023.1212851/fullesophageal squamous cell carcinomahigh-throughput drug sensitivity screening technologydrug sensitivitypatient-derived tumor xenograftstherapeutic efficacy |
| spellingShingle | Xing He Hezhong Yan Jie Hu Xiaowei Duan Mingjin Zhang Haiqing Li Jiaoxue Wang Qian Gao Senyuan Yu Xilu Hou Guobin Liao Shicun Guo Jin Li Yurong Ge Xiaolan Chen Wenchao Wang Jun Tang HDS screening with patient-derived primary cells guided individualized therapy for esophageal squamous cell carcinoma–in vivo and vitro Frontiers in Medicine esophageal squamous cell carcinoma high-throughput drug sensitivity screening technology drug sensitivity patient-derived tumor xenografts therapeutic efficacy |
| title | HDS screening with patient-derived primary cells guided individualized therapy for esophageal squamous cell carcinoma–in vivo and vitro |
| title_full | HDS screening with patient-derived primary cells guided individualized therapy for esophageal squamous cell carcinoma–in vivo and vitro |
| title_fullStr | HDS screening with patient-derived primary cells guided individualized therapy for esophageal squamous cell carcinoma–in vivo and vitro |
| title_full_unstemmed | HDS screening with patient-derived primary cells guided individualized therapy for esophageal squamous cell carcinoma–in vivo and vitro |
| title_short | HDS screening with patient-derived primary cells guided individualized therapy for esophageal squamous cell carcinoma–in vivo and vitro |
| title_sort | hds screening with patient derived primary cells guided individualized therapy for esophageal squamous cell carcinoma in vivo and vitro |
| topic | esophageal squamous cell carcinoma high-throughput drug sensitivity screening technology drug sensitivity patient-derived tumor xenografts therapeutic efficacy |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2023.1212851/full |
| work_keys_str_mv | AT xinghe hdsscreeningwithpatientderivedprimarycellsguidedindividualizedtherapyforesophagealsquamouscellcarcinomainvivoandvitro AT hezhongyan hdsscreeningwithpatientderivedprimarycellsguidedindividualizedtherapyforesophagealsquamouscellcarcinomainvivoandvitro AT jiehu hdsscreeningwithpatientderivedprimarycellsguidedindividualizedtherapyforesophagealsquamouscellcarcinomainvivoandvitro AT xiaoweiduan hdsscreeningwithpatientderivedprimarycellsguidedindividualizedtherapyforesophagealsquamouscellcarcinomainvivoandvitro AT mingjinzhang hdsscreeningwithpatientderivedprimarycellsguidedindividualizedtherapyforesophagealsquamouscellcarcinomainvivoandvitro AT haiqingli hdsscreeningwithpatientderivedprimarycellsguidedindividualizedtherapyforesophagealsquamouscellcarcinomainvivoandvitro AT jiaoxuewang hdsscreeningwithpatientderivedprimarycellsguidedindividualizedtherapyforesophagealsquamouscellcarcinomainvivoandvitro AT qiangao hdsscreeningwithpatientderivedprimarycellsguidedindividualizedtherapyforesophagealsquamouscellcarcinomainvivoandvitro AT senyuanyu hdsscreeningwithpatientderivedprimarycellsguidedindividualizedtherapyforesophagealsquamouscellcarcinomainvivoandvitro AT xiluhou hdsscreeningwithpatientderivedprimarycellsguidedindividualizedtherapyforesophagealsquamouscellcarcinomainvivoandvitro AT guobinliao hdsscreeningwithpatientderivedprimarycellsguidedindividualizedtherapyforesophagealsquamouscellcarcinomainvivoandvitro AT shicunguo hdsscreeningwithpatientderivedprimarycellsguidedindividualizedtherapyforesophagealsquamouscellcarcinomainvivoandvitro AT jinli hdsscreeningwithpatientderivedprimarycellsguidedindividualizedtherapyforesophagealsquamouscellcarcinomainvivoandvitro AT yurongge hdsscreeningwithpatientderivedprimarycellsguidedindividualizedtherapyforesophagealsquamouscellcarcinomainvivoandvitro AT xiaolanchen hdsscreeningwithpatientderivedprimarycellsguidedindividualizedtherapyforesophagealsquamouscellcarcinomainvivoandvitro AT wenchaowang hdsscreeningwithpatientderivedprimarycellsguidedindividualizedtherapyforesophagealsquamouscellcarcinomainvivoandvitro AT juntang hdsscreeningwithpatientderivedprimarycellsguidedindividualizedtherapyforesophagealsquamouscellcarcinomainvivoandvitro |